Sato-Espinoza K, Chotiprasidhi P, Liza E, Placido-Damian Z, Diaz-Ferrer J. Evolution of liver transplantation in the metabolic dysfunction-associated steatotic liver disease era: Tracking impact through time. World J Transplant 2024; 14(4): 98718 [DOI: 10.5500/wjt.v14.i4.98718]
Corresponding Author of This Article
Karina Sato-Espinoza, MD, Research Fellow, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, 200 First ST SW, Rochester, MN 55902, United States. sato.angela@mayo.edu
Research Domain of This Article
Transplantation
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Transplant. Dec 18, 2024; 14(4): 98718 Published online Dec 18, 2024. doi: 10.5500/wjt.v14.i4.98718
Evolution of liver transplantation in the metabolic dysfunction-associated steatotic liver disease era: Tracking impact through time
Karina Sato-Espinoza, Perapa Chotiprasidhi, Estefanía Liza, Zuly Placido-Damian, Javier Diaz-Ferrer
Karina Sato-Espinoza, Perapa Chotiprasidhi, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55902, United States
Estefanía Liza, Zuly Placido-Damian, Javier Diaz-Ferrer, Hepatology Service, Department of Digestive Diseases, Hospital Nacional Edgardo Rebagliati Martins, Lima 15072, Peru
Javier Diaz-Ferrer, Medicine Faculty, Universidad San Martin de Porres, Lima 02002, Peru
Javier Diaz-Ferrer, Gastroenterology Service, Clinica Internacional, Lima 02002, Peru
Author contributions: Sato-Espinoza K, Chotiprasidhi P, Liza E, Placido-Damian Z, Diaz-Ferrer J performed the methodology, wrote, reviewed, and edited the manuscript.
Conflict-of-interest statement: No conflict of interest exists for any of the authors in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Karina Sato-Espinoza, MD, Research Fellow, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, 200 First ST SW, Rochester, MN 55902, United States. sato.angela@mayo.edu
Received: July 3, 2024 Revised: August 19, 2024 Accepted: August 23, 2024 Published online: December 18, 2024 Processing time: 78 Days and 17.2 Hours
Core Tip
Core Tip: Managing liver transplantation (LT) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) presents unique challenges due to the high prevalence of obesity, diabetes, and metabolic syndrome. Pre-transplant evaluation should assess these factors to optimize patient selection and surgical outcomes. Intraoperative challenges, such as prolonged surgical times in obese MASLD patients, require careful management. Post-transplant monitoring for metabolic syndrome and cardiovascular complications is critical, as MASLD patients are at increased risk. Addressing steatosis recurrence through targeted metabolic management is crucial for long-term graft health and patient survival. A comprehensive, multidisciplinary approach is key to improving outcomes for MASLD recipients undergoing LT.
